Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 5/20 | 0.37 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | PPARG | P37231 | 4/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CTSS | P25774 | 6/20 | 0.36 |
| ▸ | CTSK | P43235 | 4/20 | 0.36 |
| ▸ | CTSL | P07711 | 1/20 | 0.36 |
| ▸ | CTSB | P07858 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | ACE | P12821 | 1/20 | 0.35 |
| ▸ | KLK7 | P49862 | 1/20 | 0.35 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.35 |
| ▸ | PPARD | Q03181 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20830134 | 0.87 | CYP3A4 (0.36) | PPARACYP3A4PPARD | |
| SCHEMBL15948875 | 0.84 | CTSK (0.37) | CYP3A4CTSK | |
| SCHEMBL23898232 | 0.81 | MMP13 (0.37) | PPARAIDO1PPARGCTSSCTSK | |
| SCHEMBL31526435 | 0.78 | IDO1 (0.40) | PPARAIDO1PPARGCYP3A4CTSS | |
| SCHEMBL22808138 | 0.78 | ATM (0.42) | CYP3A4CTSSCTSLCTSBATM | |
| SCHEMBL20975090 | 0.77 | IDO1 (0.41) | PPARAIDO1PPARGCTSSCTSK | |
| SCHEMBL20975089 | 0.77 | IDO1 (0.41) | PPARAIDO1PPARGCTSSCTSK | |
| SCHEMBL20974785 | 0.76 | PPARA (0.57) | PPARAIDO1PPARGCTSSCTSK | |
| SCHEMBL15448116 | 0.76 | PPARA (0.57) | PPARAIDO1PPARGCTSSCTSK | |
| SCHEMBL17291652 | 0.76 | PPARA (0.57) | PPARAIDO1PPARGCTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11857560-B2 | Pharmaceutical compositions comprising substituted nucleotides and nucleosides for treating viral infections | EMORY UNIVERSITY (US) | 2024-01-02 | — | — | US | disclosed |
| US-11857560-B2 | Pharmaceutical compositions comprising substituted nucleotides and nucleosides for treating viral infections | EMORY UNIVERSITY (US) | 2024-01-02 | — | — | US | disclosed |
| US-20230062181-A1 | ALKYNE CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | EMORY UNIVERSITY | 2023-03-02 | — | — | US | disclosed |
| EP-3043803-B1 | NUCLEOTIDE AND NUCLEOSIDE COMPOSITIONS AND THEIR USES | UNIV EMORY (US) | 2022-04-27 | — | — | EP | disclosed |
| US-11192914-B2 | Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto | EMORY UNIVERSITY (US) | 2021-12-07 | — | — | US | disclosed |
| US-11166973-B2 | Substituted nucleotides and nucleosides for treating viral infections | EMORY UNIVERSITY (US) | 2021-11-09 | — | — | US | disclosed |
| US-20210308168-A1 | 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-10-07 | — | — | US | disclosed |
| US-20190298750-A1 | Nucleotide and Nucleoside Therapeutic Compositions and Uses Related Thereto | DEFENSE THREAT REDUCTION AGENCY, US DOD | 2019-10-03 | — | — | US | disclosed |
| US-20190144484-A1 | ALKYNE CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | EMORY UNIVERSITY | 2019-05-16 | — | — | US | disclosed |
| US-20190085013-A1 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | UNIV EMORY (US) | 2019-03-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11192914-B2 | Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto | PNP, NTPCR, TYMP | PPARA 2939/4885IDO1 3295/4885PPARG 2843/4885 |
| US-20210308168-A1 | 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | PNP, PRPF4, HPRT1 | PPARA 1776/4885IDO1 2959/4885PPARG 1302/4885 |
| US-11166973-B2 | Substituted nucleotides and nucleosides for treating viral infections | PNP, TYMP, HPRT1 | PPARA 1572/4885IDO1 2609/4885PPARG 1457/4885 |
| US-11857560-B2 | Pharmaceutical compositions comprising substituted nucleotides and nucleosides for treating viral infections | SLC28A1, PNP, SLC28A2 | PPARA 3098/4885IDO1 2488/4885PPARG 2455/4885 |
| US-20190085013-A1 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | PNP, NTPCR, TYMP | PPARA 2318/4885IDO1 3582/4885PPARG 2631/4885 |
| US-20190144484-A1 | ALKYNE CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | TYMP, PNP, NTPCR | PPARA 2209/4885IDO1 3387/4885PPARG 2350/4885 |
| US-20230062181-A1 | ALKYNE CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | TYMP, NTPCR, PNP | PPARA 2475/4885IDO1 3465/4885PPARG 2686/4885 |
| US-20190298750-A1 | Nucleotide and Nucleoside Therapeutic Compositions and Uses Related Thereto | PNP, NTPCR, TYMP | PPARA 2318/4885IDO1 3582/4885PPARG 2631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.